0001193125-20-007844.txt : 20200115 0001193125-20-007844.hdr.sgml : 20200115 20200115121509 ACCESSION NUMBER: 0001193125-20-007844 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200115 DATE AS OF CHANGE: 20200115 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ACORDA THERAPEUTICS INC CENTRAL INDEX KEY: 0001008848 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-81801 FILM NUMBER: 20527772 BUSINESS ADDRESS: STREET 1: 420 SAW MILL RIVER ROAD CITY: ARDSLEY STATE: NY ZIP: 10502 BUSINESS PHONE: 914-347-4300 MAIL ADDRESS: STREET 1: 420 SAW MILL RIVER ROAD CITY: ARDSLEY STATE: NY ZIP: 10502 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: SYMPHONY ASSET MANAGEMENT LLC CENTRAL INDEX KEY: 0001030815 IRS NUMBER: 943252504 STATE OF INCORPORATION: CA FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 555 CALIFORNIA STREET STREET 2: SUITE 3100 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 4156764000 MAIL ADDRESS: STREET 1: 555 CALIFORNIA STREET STREET 2: SUITE 3100 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 SC 13G 1 d874099dsc13g.htm SYMPHONY ASSET MANAGEMENT LLC SYMPHONY ASSET MANAGEMENT LLC

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(AMENDMENT NO.    )*

Acorda Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

00484M106

(CUSIP Number)

December 31, 2019

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☒ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

  1  

NAME OF REPORTING PERSON

 

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

 

Symphony Asset Management, LLC              94-3252504

  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)  ☐        (b)  ☐

 

N/A

  3  

SEC USE ONLY

 

  4  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware - U.S.A.

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING

PERSON

WITH

    5    

SOLE VOTING POWER

 

4,633,427 (based upon conversion of bonds CUSIP 00484MAB2)

   6   

SHARED VOTING POWER

 

0

   7   

SOLE DISPOSITIVE POWER

 

4,633,427 (based upon conversion of bonds CUSIP 00484MAB2)

   8   

SHARED DISPOSITIVE POWER

 

0

  9  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

4,633,427 (based upon conversion of bonds CUSIP 00484MAB2)

10  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

N/A

11  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

9.647%

12  

TYPE OF REPORTING PERSON*

 

IA

Item 1(a)    Name of Issuer:
   Acorda Therapeutics, Inc.
Item 1(b)    Address of Issuer’s Principal Executive Offices:
   420 Saw Mill River Road
   Ardsley, NY 10502
Item 2(a)    Name of Person Filing:
   Symphony Asset Management, LLC
Item 2(b)    Address of the Principal Office or, if none, Residence:
   555 California Street, Suite 3100
   San Francisco, CA 94104
Item 2(c)    Citizenship:
   California – U.S.A.
Item 2(d)    Title of Class of Securities:
   Common Stock
Item 2(e)    CUSIP Number:
   00484M106
Item 3    If the Statement is being filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:
   (e)    ☒    An investment advisor in accordance with section 240.13d-1(b)(1)(ii)(E)
Item 4    Ownership:
   (a)    Amount Beneficially Owned:
      4,633,427 (based upon conversion of bonds CUSIP 00484MAB2)
   (b)    Percent of Class:
      9.647%
   (c)    Number of shares as to which such person has:
   (i)    sole power to vote or direct the vote:
      4,633,427 (based upon conversion of bonds CUSIP 00484MAB2)
   (ii)    shared power to vote or direct the vote:
      0
   (iii)    sole power to dispose or to direct the disposition of:
      4,633,427 (based upon conversion of bonds CUSIP 00484MAB2)
   (iv)    shared power to dispose or to direct the disposition of:
      0
Item 5    Ownership of Five Percent or Less of a Class:
   Not applicable.

Item 6       Ownership of More than Five Percent on Behalf of Another Person:
      Securities reported on this Schedule 13G are beneficially owned by clients which may include investment companies registered under the Investment Company Act and/or employee benefit plans, pension funds, endowment funds or other institutional clients.
Item 7       Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
      Not applicable.
Item 8       Identification and Classification of Members of the Group:
      Not applicable.
Item 9       Notice of Dissolution of a Group:
      Not applicable.
Item 10       Certification:
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of such securities and were were not acquired in connection with or as a participant in any transaction having such purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: January 15, 2020    
    Symphony Asset Management, LLC
    By:  

/S/ Geoffrey W. Moore

    Name:   Geoffrey W. Moore
    Title:   Chief Compliance Officer